Xeljanz lost its market lead by falling sales by 13% due to safety issues. The market for JAK inhibitors, an oral autoimmune disease treatment drug, is fluctuating. While long-time market leader Pfizer Xeljanz faltered, Lilly's Oluminant took the lead. On top of that, Abbvie Rinvoq quickly expanded its sales, signaling fierce competition.

◆↑ Olumiant 30% of sales

According to IQVIA, a pharmaceutical market research firm, Oluminant's cumulative sales in the third quarter of this year were 11.7 billion won. It increased by 30% compared to the cumulative 9 billion won in the third quarter of last year.

Oluminant is a drug used for autoimmune diseases such as rheumatoid